Side effects:
Common effects reported in clinical trials are dizziness, headache, depression, dyspnea, upper abdominal pain, abdominal distension, diarrhea, nausea, vomiting, ascites, rashes, pruritus, muscle spasms, arthralgia and peripheral oedema.

Other effects that have been reported include: Clostridial infections, urinary tract infections, candidiasis, pneumonia cellullitis, upper respiratory tract infection and rhinitis. Blood disorders (e.g. anaemia, thrombocytopenia). Anaphylactic reactions, angioedemias, hypersensitivity. Anorexia, hyperkalaemia and dehydration. Confusion, sleep disorders, balance disorders, convulsions, hypoesthesia, memory impairment and attention disorders. Hypotension, hypertension and fainting. Hot flushes. Breathing difficulty, pleural effusion, COPD. Gastrointestinal disorders and skin reactions. Liver function test abnormalities. Dysuria, pollakiuria and proteinuria. Oedema. Pyrexia. INR abnormalities.

Prescribers should consult the SmPC in relation to all adverse reactions.

UNITED KINGDOM
Legal category: POM
Cost: Basic NHS price £259.23 for 56 tablets
Marketing Authorisation holder: Norgine Pharmaceuticals Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK
Marketing Authorisation number: PL 20011/0020

IRELAND
Legal category: Prescription only
Cost: €262.41 for 56 tablets
Marketing Authorisation holder: Norgine B.V. Antonio Vivaldistraat 150, 1083 HP, Amsterdam, Netherlands
Marketing Authorisation number: PA 1336/009/001

For further information contact:
Norgine Pharmaceuticals Limited
Moorhall Road
Harefield
Middlesex, UB9 6NS
Telephone: 01895 826 606
E-mail: Medinfo@norgine.com

Ref: UK/XIF5/0519/0509
Date of preparation: May 2019